NasdaqGM:NAMSBiotechs
Does NewAmsterdam Pharma's Sharp Q3 Revenue Drop Reshape the Bull Case for NAMS?
On November 5, 2025, NewAmsterdam Pharma reported third quarter results showing sales fell to US$348,000 from US$29.11 million a year earlier, with net loss widening to US$72.01 million.
Despite the sharp quarterly setback, the company's nine-month net loss and loss per share were smaller compared to the same period last year.
We’ll explore how the sharp revenue contraction in the quarter shapes the current investment narrative for NewAmsterdam Pharma.
AI is about to change healthcare. These...